Preclinical News and Research

RSS

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.

27 Nov 2012

Fujitsu advances healthcare innovation in collaboration with National University of Singapore

Fujitsu Laboratories of Europe Limited, Fujitsu Asia Pte Ltd and the National University of Singapore (NUS) today announced an important collaboration to establish a new joint research programme - Body Sensor Network for Disease Management and Prevention-Oriented Healthcare. Fujitsu will be working closely with the Department of Electrical and Computer Engineering at the NUS Faculty of Engineering, as well as the NUS Yong Loo Lin School of Medicine and the NUS Saw Swee Hock School of Public Health.

26 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Weight loss and quality of sleep: an interview with Kerry Stewart

In our particular study we used a survey which consisted of 50 different questions which get at different aspects of sleep health. It was a patient self-report.

26 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Several fatal brain disorders, including Parkinson's disease, are connected by the misfolding of specific proteins into disordered clumps and stable, insoluble fibrils called amyloid. Amyloid fibrils are hard to break up due to their stable, ordered structure. For example, α-synuclein forms amyloid fibrils that accumulate in Lewy Bodies in Parkinson's disease. By contrast, protein clumps that accumulate in response to environmental stress, such as heat shock, possess a less stable, disordered architecture.

20 Nov 2012

Boston and Cincinnati Children's Hospital to learn more about how autism develops

A network of five leading medical centers, led by Cincinnati Children's Hospital Medical Center and Boston Children's Hospital, has received a five-year, $12.5 million National Institutes of Health (NIH) grant to learn more about how autism develops.

20 Nov 2012

CFFT announces major expansion of research collaboration with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

20 Nov 2012

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

The adverse side effects of certain hepatitis C medications can now be replicated and observed in Petri dishes and test tubes, thanks to a research team led by Craig Cameron, the Paul Berg Professor of Biochemistry and Molecular Biology at Penn State University.

17 Nov 2012

HUCPVC cell therapy more effective in restoring heart function after myocardial infarction

A study published this month by researchers at the University of Toronto and Toronto's Princess Margaret Hospital has shown that cells derived from the umbilical cord, "Human Umbilical Cord PeriVascular Cells" (HUCPVCs), are more effective in restoring heart function after an acute myocardial infarction (in common parlance, a heart attack) in a pre-clinical model than a similar cell population derived from bone marrow.

16 Nov 2012

Courtagen, AGBL enter exclusive distribution agreement for clinical tests

Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Age at onset of first menstrual cycle associated with increased BMI, obesity in adulthood

Age at onset of menarche (first menstrual cycle) is associated with increased body mass index (BMI), waist circumference, and overall obesity in adulthood, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

15 Nov 2012

New gene delivery vehicle opens route to the heart of cells in solid tumors

There are plenty of effective anticancer agents around. The problem is that, very often, they cannot gain access to all the cells in solid tumors. A new gene delivery vehicle may provide a way of making tracks to the heart of the target.

15 Nov 2012

Lung cancer stem cells can be isolated and grown in preclinical models

A University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolated-and then grown-in a preclinical model, offering a new avenue for investigating immunotherapy treatment options that specifically target stem cells.

14 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Malaria Box helps identify three chemical series that target treatment of NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.

14 Nov 2012

Preclinical News and Research

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

Fujitsu advances healthcare innovation in collaboration with National University of Singapore

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Weight loss and quality of sleep: an interview with Kerry Stewart

mRNA vaccines offer protection against influenza A virus infections in various animal models

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Boston and Cincinnati Children's Hospital to learn more about how autism develops

CFFT announces major expansion of research collaboration with Pfizer

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

HUCPVC cell therapy more effective in restoring heart function after myocardial infarction

Courtagen, AGBL enter exclusive distribution agreement for clinical tests

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Age at onset of first menstrual cycle associated with increased BMI, obesity in adulthood

New gene delivery vehicle opens route to the heart of cells in solid tumors

Lung cancer stem cells can be isolated and grown in preclinical models

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Malaria Box helps identify three chemical series that target treatment of NTDs

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics